Astellas Pharma Inc. Buys Maxygen, Inc.'s Stake in Protein Drug Firm for $76M

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY) today announced that Astellas Pharma Inc. has exercised its option to purchase all of Maxygen’s equity interests in Perseid Therapeutics LLC at the current exercise price of $76.0 million.

Back to news